New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:22 EDTSGEN, ABBV, RHHBYSeattle Genetics announces data from several collaborator ADC programs
Seattle Genetics (SGEN) announced data from several collaborator antibody-drug conjugate, ADC, programs presented at the American Society of Clinical Oncology, ASCO, 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. AbbVie (ABBV) presented preliminary data from an ongoing phase 1 clinical trial evaluating the ADC ABT-414 in combination with temozolomide in glioblastoma, and Genentech, a member of the Roche Group (RHHBY), is presenting data from five ADC programs, including two oral presentations. In addition, Progenics presented data from an ADC program under evaluation for castration-resistant prostate cancer. All of the collaborator programs utilize Seattle Genetics’ ADC technology. “Researchers at Seattle Genetics have identified and optimized novel components that are fundamental to creating antibody-drug conjugates, including potent cell-killing agents and conditionally stable linker systems,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. “Our collaborators are making great progress in advancing novel ADC candidates as evidenced by the encouraging data presentations at ASCO. Seattle Genetics continues to lead the field in developing ADC candidates, which demonstrate the therapeutic potential of our technology broadly through both our proprietary and collaborator programs.”
News For SGEN;ABBV;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
18:49 EDTABBVEnanta will not exercise co-development option for ABT-493
Enanta Pharmaceuticals (ENTA) announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus, or HCV, being developed in Enanta’s collaboration with AbbVie (ABBV). Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens. Enanta also announced that it has reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.
17:34 EDTABBVAbbVie announces new $5B stock repurchase program, raises dividend nearly 17%
Subscribe for More Information
17:33 EDTABBVAbbVie announces new $5B stock repurchase program, raises dividend
17:26 EDTABBVShire down 1% following termination of merger with AbbVie
Subscribe for More Information
17:17 EDTABBVAbbVie to pay Shire $1.64B break fee
Subscribe for More Information
17:16 EDTABBVAbbVie, Shire announce termination of proposed merger
Subscribe for More Information
17:14 EDTABBVAbbVie, Shire announce termination of proposed merger
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:47 EDTABBVPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBY, ABBVAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
06:56 EDTABBVShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 17, 2014
16:55 EDTABBVStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:47 EDTABBVAbbVie initiated with a Buy at ISI Group
Subscribe for More Information
07:07 EDTABBVShire may be buyer instead of target if AbbVie deal breaks, WSJ says
Assuming AbbVie's (ABBV) deal to buy Shire (SHPG) gets cancelled, which appears likely at this point, many analysts and investors believe Shire will become a buyer and Leerink Partners estimates the company could have $10B to use for a takeover deal, reported The Wall Street Journal. AbbVie will also be likely to look for other deals and could be forced to pay up for them, as its top seller, Humira, moves closer to losing patent exclusivity, the Journal said, citing analysts. Reference Link
05:55 EDTABBVStocks with implied volatility movement; ABBV CSX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use